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and David N. Irani
Lymphoid chemokines are crucial for the development and maintenance of lymphoid organs, but their ectopic expression in
non-lymphoid tissues is implicated in both local response to infection and chronic organ-specific autoimmunity. Production of
one such chemokine, C-X-C motif ligand 13 (CXCL13), within the central nervous system (CNS) has been linked to the patho-
genesis of multiple sclerosis (MS), although little is known about factors controlling its expression in different neural cell types
and across a range of disease states. We provoked acute neuroinflammation in experimental animals without causing any
associated demyelination using neuroadapted Sindbis virus (NSV) to better understand the sources and regulators of this che-
mokine in the CNS. We found that mice genetically deficient in the transcription factor, interferon (IFN) regulatory factor-7
(IRF7), made significantly higher CXCL13 protein levels in the CNS compared with wild-type (WT) controls. Microglia proved
to be the main producer of CXCL13 in the brain during infection of both WT and IRF72/2 mice, and primary microglia cul-
tured in vitro generated CXCL13 following stimulation with either virus particles or synthetic Toll-like receptor (TLR) ligands.
Microglia cultured from IRF72/2 mice selectively overproduced CXCL13, and manipulation of extracellular type-I IFN levels
demonstrated the existence of a negative feedback loop whereby type-I IFN receptor signaling specifically suppressed micro-
glial CXCL13 release. Since IFN-b is used to treat patients with relapsing-remitting MS and yet acts through unknown mecha-
nisms, we speculate that suppressed lymphoid chemokine production by microglia could contribute to its therapeutic effects.
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Introduction
Lymphoid chemokines are molecules constitutivelyexpressed in lymphoid organs that recruit and compart-
mentalize lymphocytes and antigen presenting cells into and
within these highly specialized structures (Allen et al., 2004;
Ansel et al., 2000; Campbell et al., 2003; Forster et al., 1996;
Fu and Chaplin, 1999; Legler et al., 1998; Mackay and
Browning, 1998; Moser et al., 2002; Muller et al., 2003;
Ngo et al., 1999; Yoshie et al., 1997; Zlotnik et al., 1999).
C-C motif ligand (CCL) 19 and CCL21 bind to C-C motif
receptor (CCR) 7 and recruit T cells and dendritic cells (DC)
to T cell areas of secondary lymphoid tissues (Legler et al.,
1998; Yoshie et al., 1997). C-X-C motif ligand (CXCL) 12
binds to C-X-C motif receptor (CXCR) 4 and attracts multi-
ple immune cell types to lymph nodes and spleen, and along
with CXCL13, drives the formation of germinal centers
(Allen et al., 2004; Campbell et al., 2003). CXCL13 is made
by stromal cells in B cell follicles, and recruits both B cells
and T follicular helper (Tfh) cells to these compartments by
signaling through its cognate receptor, CXCR5 (Allen et al.,
2004; Ansel et al., 2000; Campbell et al., 2003; Forster et al.,
1996; Legler et al., 1998; Moser et al., 2002; Muller et al.,
2003). The expression of all lymphoid chemokines in both T
and B cell areas of lymphoid organs depends on lymphotoxin
(LT)-b and tumor necrosis factor (TNF)-a signaling in stro-
mal cells that normally produce these chemoattractant
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molecules within these specialized tissues (Fu and Chaplin,
1999; Mackay and Browning, 1998; Ngo et al., 1999).
Beyond its role in the development and maintenance of
lymphoid tissues, CXCL13 has also been implicated in the
propagation of non-lymphoid tissue inflammation. Chronic
gastrointestinal infection of humans with Helicobacter pylori
causes the formation of mucosa-associated lymphoid struc-
tures that contain CXCL13 (Mazzucchelli et al., 1999), and
antibody-mediated neutralization of CXCL13 in experimental
animals directly inhibits this process (Yamamoto et al., 2014).
Data generated in other infection models also point to a role
for CXCL13 in recruiting B cells to organs such as the lung
or the liver where it helps organize local immune responses
against influenza and hepatitis B, respectively (Publicover
et al., 2013; Rangel-Moreno et al., 2007). On the other
hand, ectopic structures resembling T and B cell follicles are
found in the synovia of patients with rheumatoid arthritis
and in the salivary glands of patients with Sj€ogren’s disease
(Hjelmstrom, 2001), and transgenic expression of CXCL13
in an organ such as the pancreas is sufficient to cause the for-
mation of ectopic lymphoid structures and produce laboratory
evidence of diabetes (Luther et al., 2000). CXCL13 is also
found in B cell aggregates that develop in the inflamed
meninges of mice with experimental autoimmune encephalo-
myelitis (EAE) and humans with progressive multiple sclerosis
(MS) (Aloisi et al., 2008; Magliozzi et al., 2004, 2007; Peters
et al., 2011; Serafini et al., 2004). These data imply that the
CXCL13-driven formation of ectopic lymphoid structures
may be a natural feature of both organ-specific antimicrobial
and autoimmune inflammation (Hjelmstrom, 2001; Lalor
and Segal, 2010; Magliozzi et al., 2007; Serafini et al., 2004).
Within the central nervous system (CNS), recent reports
describe elevated CXCL13 concentrations in the cerebrospinal
fluid (CSF) of patients with either relapsing-remitting multi-
ple sclerosis (RRMS) or neuromyelitis optica (NMO) com-
pared with controls, and that levels are higher during active
disease relapses and decline with successful therapy (Brettsch-
neider et al., 2010; Khademi et al., 2011; Krumbholz et al.,
2006; Piccio et al., 2010; Ragheb et al., 2011; Sellebjerg
et al., 2009; Zhong et al., 2011). Quantitative PCR analysis
of autopsy brain tissue from MS patients demonstrates that
cxcl13 gets selectively induced in active versus inactive MS
lesions, and immunostaining of tissue sections shows
CXCL13 protein within and around active MS plaques
(Krumbholz et al., 2006). In tissue samples from patients
with late-stage progressive MS, some specimens also demon-
strate CXCL13 staining in B cell-containing follicles that
develop along the meninges and deep within the sulci of the
brain (Magliozzi et al., 2007; Serafini et al., 2004). These
meningeal lymphoid follicles are hypothesized to be sites
where myelin-specific T and B cells get reactivated in response
to their cognate antigens thus propagating autoimmune dam-
age to the brain and spinal cord (Lalor and Segal, 2010). Lit-
tle, however, is known about factors controlling the local
expression of CXCL13 in the CNS during a wide range of
disease states.
We used neuroadapted Sindbis virus (NSV) to provoke
acute neuroinflammation without any associated demyelin-
ation in experimental animals in order to investigate the sour-
ces and factors regulating CNS expression of CXCL13 in
response to a biologically relevant stimulus. We found that
mice genetically deficient in the transcription factor, inter-
feron (IFN) regulatory factor-7 (IRF7), a critical intermediate
in the type-I IFN response, made significantly higher CNS
levels of CXCL13 protein compared with wild-type (WT)
controls. Microglia were the main source of CXCL13 pro-
duced in the CNS during this infection, and primary micro-
glia cultured in vitro secreted CXCL13 following stimulation
with virus particles or particular Toll-like receptor (TLR)
ligands. Microglia cultured from the brains of IRF72/2 mice
selectively overproduced CXCL13 in vitro, and manipulation
of extracellular type-I IFN levels demonstrated the existence
of a negative feedback loop whereby type-I IFN receptor
(IFNAR) signaling specifically suppressed microglial CXCL13
release. We speculate this feedback loop could impact host
responses against certain viral pathogens that invade the
CNS. It could also be relevant to the pathogenesis of MS,
since exogenous IFN-b is a well-established treatment for
patients with the relapsing-remitting form of this disease.
Materials and Methods
Animals
Wild-type C57BL/6 mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME). Mice rendered genetically deficient in IRF7,
CXCL13, and IFNAR were generous gifts from the laboratories of
Dr. Gabriel Nunez, Dr. Benjamin Segal and Dr. Steven Kunkel,
respectively. IRF7/CXCL13 double deficient mice were generated de
novo and bred on site. Animals were maintained and used under spe-
cific pathogen-free conditions in strict accordance with guidelines set
by the National Institutes of Health and protocols approved by our
University Committee on the Use and Care of Animals. Mice were
housed on a 10 h light/14 h dark cycle in ventilated cages, each con-
taining no more than five animals. Food and water were available ad
libitum.
Induction of Viral Encephalitis and Manipulation of
Virus-Infected Animals
To induce encephalomyelitis, 6-week-old mice were anesthetized
with isoflurane and 1000 plaque forming units (PFU) of NSV, sus-
pended in 10 lL of phosphate-buffered saline (PBS), was inoculated
directly into the right cerebral hemisphere of each animal. Most
cohorts of infected mice were then monitored daily for survival in
accordance with approved animal protocols. Some groups of live
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animals were euthanized at defined intervals postinfection to collect
brain and spinal cord tissue for further analysis, including moribund
IRF72/2 mice on day 5 postinfection. Here, CNS tissues were col-
lected following intracardiac perfusion with ice-cold PBS, weighed,
snap frozen at 280C, and used to generate tissue homogenates for
virus titration assays or enzyme linked immunosorbent assays (ELI-
SAs) (see below). In other cohorts, PBS-perfused brain tissue was
used to isolate individual cell populations via a flow cytometry-based
cell sorting protocol (see below).
Flow Cytometry-Based Separation of Discrete
Immune and Glial Cell Populations from the CNS of
Virus-Infected Mice
Perfused brains taken from virus-infected WT or IRF72/2 animals
were minced into small fragments and pressed through a 70 lM
stainless steel mesh sieve into Hank’s balanced salt solution (HBSS)
containing 10% fetal bovine serum (FBS). The resultant tissue
homogenate was digested with 0.2 mg/mL collagenase (Worthington
Biochemical Corp., Lakewood, NJ) and 28 units/mL DNase
(Sigma–Aldrich, St. Louis, MO) for 40 min at 37C. Mononuclear
cells were then isolated from the digested tissue slurry via centrifuga-
tion over 30%/70% Percoll gradients (GE Healthcare Life Sciences,
Pittsburgh, PA), and cells recovered from gradient interfaces were
counted and washed thoroughly with HBSS. Cells pooled from 10
WT or 10 IRF72/2 mice on day 4 postinfection were then sus-
pended in PBS containing 2% FBS and stained using a combination
of fluorescently tagged anti-CD45 and anti-CD11b antibodies (BD
Biosciences, San Jose, CA). After gating on live intact cells, three eas-
ily defined and discrete mononuclear cell populations were identified
and sorted using a MoFlo XDP High-Speed Cell Sorter (Beckman-
Coulter, Indianapolis, IN): CD45high/CD11b- (infiltrating lymph-
oid) cells, CD45high/CD11b1 (infiltrating myeloid) cells, and
CD45dim/CD11b1 (endogenous microglial) cells. Individual cell
populations were sorted, washed in PBS and stored at 220C in
PrepProtect RNA stabilization solution (Miltenyi Biotec, Auburn,
CA) until final RNA isolations were performed.
Preparation and Use of Primary Microglial Cultures
Primary microglia were isolated and cultured from the cortices of 2-
to 3-day-old WT or IRF72/2 mice as described (Esen and Kielian,
2005). When mixed glial cultures reached confluency after 7 to 10
days, flasks were shaken overnight at 200 rpm at 37C to detach
microglia from the more firmly adherent astrocytes. Cells in suspen-
sion (>95% pure CD11b1 microglia) were collected and 1 3 105
cells plated into each well of 96-well plates. The next day, microglia
were stimulated either with NSV or a known TLR ligand for 24 h
in a total volume of 200 lL. To generate inactivated NSV particles,
virus was exposed to ultraviolet (UV) light generated by a germicidal
lamp (wavelength5 254 nm) at a distance of 5 cm for 1 h at 25C.
Virus inactivation was confirmed by standard plaque titration assays
(described below). Stimuli included: PBS (referred to as control in
all our in vitro assays), 1 3 106, 1 3 107, or 1 3 108 pfu NSV
(corresponding to virus particle-to-cell ratios of 10:1, 100:1 or
1,000:1, respectively), 1 3 106, 1 3 107, or 1 3 108 pfu UV-
inactivated NSV, 100 ng/mL Escherichia coli LPS (List Biological
Laboratories, Campbell, CA) as a TLR4 stimulus, 25 mg/mL polyi-
nosinic:polycytidylic acid (poly(I:C), Invivogen) as a TLR3 stimulus,
1 mM loxoribine (Invivogen, San Diego, CA) as a TLR7 stimulus
or 3 lM unmethylated DNA oligodeoxynucleotides bearing CpG
motifs (CpG-ODN) (Invivogen) as a TLR9 stimulus. Some cultures
were also performed in the presence of exogenous recombinant
mouse IFN-a (PBL Interferon Source, Piscataway, NJ) at described
doses. At the end of the stimulation period, culture supernatants
were collected and stored at 280C until cytokine and chemokine
ELISAs could be performed. Microglial viability was assayed using
the well-established 3-(4,5-dimethylthiazol-2-yl)22,5-diphenyl-2H-
tetrazolium bromide (MTT) assay. Infectious virus was assayed in
culture supernatants to screen for productive infection of microglial
cells using a standard plaque titration assay as described (Irani and
Prow, 2007; Liang et al., 1999; Tucker et al., 1996). Some cells were
washed in PBS and stored at 220C in PrepProtect RNA stabiliza-
tion solution (Miltenyi Biotec) until final RNA isolations were
performed.
Cytokine and Chemokine Assays
Frozen tissue homogenates were thawed, minced, and homogenized
in 0.5 mL of PBS containing a protease inhibitor cocktail and an
RNase inhibitor (both from Sigma-Aldrich). After homogenates were
centrifuged to pellet all the remaining tissue debris, total protein
content was measured in each extract and supernatants were further
diluted in PBS to a normalized total protein concentration. Micro-
glial culture supernatants were used without further manipulation.
Levels of individual cytokines and chemokines were measured
directly in samples using commercial sandwich ELISA kits according
to the manufacturers’ instructions. Results from tissue samples reflect
the mean6 SEM of the pg of cytokine/mg of tissue extracted pro-
tein derived from a minimum of three animals at each time point.
Data from culture supernatants reflect the mean6 SEM pg of che-
mokine/mL of culture supernatant derived from triplicate cell culture
wells. Quantification of TNF-a, interleukin (IL)212p40, and CCL2
levels was performed using mouse OptEIA kits (BD Biosciences),
CXCL12 and CXCL13 levels were measured using Duoset mouse
ELISA kits (R&D Systems, Minneapolis, MN), IFN-a and IFN-b
levels were determined using mouse VeriKine ELISA kits (PBL Inter-
feron Source), CCL19 concentrations measured by a mouse ELISA
kit (Abcam, Cambridge, MA), and CCL21 levels determined by a
mouse ELISA kit (Sigma-Aldrich). The lower limit of detection for
these assays was typically 15.6 pg/mL.
PCR Quantification of CXCL13 Transcripts in
Distinct CNS-Derived Cell Populations
Samples prepared from each CNS flow sorted or cultured microglial
cell population were carefully thawed and removed from the Pre-
pProtect RNA stabilization solution. Total RNA was isolated from
each sample using QIAshredder Kit and the RNeasy Mini Kit
according to the manufacturer’s instructions (Qiagen, Germantown,
MD). A cDNA template was then generated from each sample using
the SuperScriptVR III First Strand Synthesis System for reverse tran-
scriptase–PCR (Invitrogen, Carlsbad, CA). Semi-quantitative PCR
was undertaken using the MyiQ Single Color Real-Time PCR
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Detection System (Bio-Rad Laboratories, Hercules, CA) and the
cxcl13 primer/probe set in the TaqManVR Gene Expression Assay
(Applied Biosystems Inc., Foster City, CA). Data were analyzed
against a b-actin mRNA standard and are shown as relative cxcl13
mRNA expression. For the flow-sorted cell populations, expression
values were then normalized to the level present in CD45high/
CD11b1 cells isolated from WT mice assigned an arbitrary level of
1.0. For the cultured microglial cells, expression values were then
normalized to the level present in vehicle-treated (control) WT cells
assigned an arbitrary level of 1.0 (Fig. 3D) or to the level present in
IRF72/2 cells assigned an arbitrary level of 1.0 (Fig. 4D).
Statistical Analyses
The Prism 5.0 software package (GraphPad Software Inc., La Jolla,
CA) was used for all statistical analyses. Differences in survival
among cohorts of mice were measured using a log-rank (Mantel-
Cox) test. Unpaired Student’s t test was used to assess differences
between different experimental groups at a single time point. A two-
way analysis of variance (ANOVA) test was applied when comparing
different experimental groups over time. In all cases, differences at a
P < 0.05 level were considered significant.
Results
High Levels of CXCL13 are Produced in the CNS of
Mice who fail to Mount a Robust Type-I IFN
Response During Virus-Induced Neuroinflammation
Host factors strongly influence disease outcome in mice with
NSV encephalitis, and early innate immune responses are par-
ticularly important determinants of survival (Liang et al.,
1999; Tucker et al., 1996). To investigate the role of IRF7
and type-I IFN in disease pathogenesis, WT and IRF72/2
mice were subjected to lethal NSV challenge. Survival assays
showed heightened disease susceptibility among IRF72/2
mice compared with WT controls (Fig. 1A). Measurement of
tissue viral titers showed evidence of unrestrained virus repli-
cation in the CNS of the IRF72/2 cohort (Supp. Info. Fig.
S1), while analysis of tissue homogenates showed negligible
FIGURE 1: IRF7 controls both CXCL13 levels in the brain and spinal cord as well as disease outcome during lethal neuroadapted SV
(NSV) encephalitis in mice. A. IRF72/2 mice are highly susceptible to a lethal NSV challenge compared with WT control animals (n 5 16
per group). B–E. Neither IFN-a nor IFN-b is induced in the brains or spinal cords of IRF72/2 mice at any stage of infection prior to death.
F, G. This heightened disease susceptibility in IRF72/2 mice is associated with unrestrained CXCL13 production in both CNS compart-
ments of infected animals over time. H, I. CXCL13 is not pathogenic during NSV infection in either WT (n 5 12 per group) or IRF72/2
mice (n 5 10 per group) as its deletion from either host did not confer any protection against disease.
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induction of either type-I IFN in the CNS of these animals
(Fig. 1B–E). To better understand the downstream conse-
quences of IRF7 and type-I IFN deficiency in this setting,
multiple inflammatory mediators were measured in both
brain and spinal cord tissues derived from these two hosts.
One of the most notable differences related to tissue levels of
the lymphoid chemokine, CXCL13; protein concentrations
were up to 10-fold higher in the CNS of IRF72/2 animals
over the course of acute infection (Fig. 1F,G). Nonetheless, a
detrimental effect of CXCL13 on disease outcome could not
be demonstrated, as deletion of cxcl13 from either WT or
IRF72/2 hosts had no impact on their survival following
NSV challenge (Fig. 1H,I). Still, these in vivo data suggested
that IRF7 and the type-I IFN it produces could be negative
regulators of CXCL13 expression in the CNS.
Microglia are the Main Source of CXCL13
Transcripts in the CNS During Virus-Induced
Neuroinflammation
To identify the cellular source of CXCL13 in the CNS during
NSV infection, candidate mononuclear cell populations
derived from either WT or IRF72/2 animals were sorted
from one another by flow cytometry based on different pat-
terns of CD11b and CD45 expression (Fig. 2A). Total cellu-
lar RNA was then extracted from each population of cells
that had been pooled from the brains of multiple WT or
IRF72/2 mice on day 4 post-infection, and relative cxcl13
mRNA levels were quantified compared with a b-actin
mRNA standard. Pilot studies confirmed that CD45neg cells
isolated from the CNS of either host did not express cxcl13
(data not shown), consistent with our previous in vitro data
showing that non-hematopoietic neural cells such as astrocytes
do not produce this mediator in response to virus challenge
(Rainey-Barger et al., 2011). Amongst the three isolated
CD451 cell subsets, cxcl13 transcripts predominated in
CD45dim/CD11b1 microglia (sorted population 2) derived
from both WT and IRF72/2 mice (Fig. 2B). These
CD45dim/CD11b1 cells proved to be slightly more abundant
in the brains of the IRF72/2 cohort, although the difference
was not significant (Fig. 2C). Since CXCL13 was not likely
being made by another CNS cell type in IRF72/2 mice, and
FIGURE 2: Microglia are the principal source of CXCL13 produc-
tion in the CNS during NSV encephalitis in mice. A. Mononuclear
cells were isolated from the brains of 10 WT and 10 IRF72/2 ani-
mals on day 4 post-infection as described in Materials and Meth-
ods. Using flow cytometry to gate on intact cells, individual
mononuclear populations were separated based on CD11b
expression, then on CD45 levels. Pooled CD45high/CD11b-
lymphoid cells (population 1), CD45dim/CD11b1 microglia (popu-
lation 2) and CD45high/CD11b1 monocytes (population 3) were
then used for RNA extraction and quantitative PCR as described
in Materials and Methods. B. Relative cxcl13 mRNA levels, first
normalized to b-actin transcript levels and then to expression
levels in CD45high/CD11b1 myeloid cells from WT mice, were
then determined for each of the three populations of CNS-
derived cells from either WT or IRF72/2 animals. C. CD45dim/
CD11b1 microglial cell numbers present in the brains of WT and
IRF72/2 mice at this stage of disease were not significantly dif-
ferent from one another (P50.12).
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because there was not a dramatic increase in the numbers of
activated microglia in the brains of these hosts (Fig. 2C),
these gene expression data infer that differences in CXCL13
protein levels present in CNS tissue homogenates from
infected mice (Fig. 1F,G) derive from an effect of IRF7 or
type-I IFN acting at a translational or post-translational level.
They also clearly identify microglia as being the principal
mononuclear cell source of CXCL13 in the CNS during
NSV encephalitis.
Type-I IFN Regulates CXCL13 Production by
Primary Microglia In Vitro
Microglial activation is an early neuropathological finding
observed in mice infected with NSV (Irani and Prow, 2007,
Prow and Irani, 2007). Nonetheless, the various receptors,
signaling pathways, and soluble mediators either acting upon
or produced by these innate immune cells during infection
remain poorly defined. Using primary microglial cell cultures,
we found that both NSV as well as a synthetic TLR9 ligand
induced measurable CXCL13 production in vitro (Fig. 3A).
Ligands specific for TLR3, TLR4, and TLR7 did not elicit
this response (Fig. 3A), nor did any of these stimuli trigger
microglia to produce other lymphoid chemokines, including
CXCL12, CCL19, or CCL21 (Supp. Info. Fig. 2). At no
point did exposure to the virus cause productive infection or
diminished viability of these innate immune cells (Supp. Info.
Fig. 3). Any residual astrocytes that might contaminate our
microglial cultures were not considered to be a likely source
of CXCL13 based on our prior data showing that these cells
do not produce this mediator following virus exposure
FIGURE 3: Specific ligands and signaling pathways control cytokine and chemokine production by primary microglial cells in vitro. A.
Both NSV and a synthetic TLR9 agonist provoked microglial CXCL13 production that was not induced using agonists specific for TLR3,
TLR7, or TLR4 (*P<0.05 vs. unstimulated control cultures). B. This NSV-induced release of CXCL13 by microglia varied approximately
twofold across a 100-fold difference in the ratio of virus particles to target cells, and it was not elicited by UV-inactivated virus. C.
CXCL13 release was significantly higher in IRF72/2 versus WT cells (*P<0.05 in IRF72/2 vs. WT cultures; yP<0.05 in stimulated vs. unsti-
mulated IRF72/2 cultures). D. cxcl13 transcripts were higher at baseline and following NSV stimulation in IRF72/2 versus WT cells. E–G.
Stimulated production of selected other cytokines and chemokines was not different between WT and IRF72/2 microglia. H, I. Cells
from IRF72/2 mice did not produce measurable amounts of either IFN-a or IFN-b in response to any of the stimuli examined.
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(Rainey-Barger et al., 2011). Production of CXCL13
increased somewhat in proportion to the amount of NSV
added to the cultures, while UV-inactivated virus failed to
trigger microglial CXCL13 release (Fig. 3B). This finding is
consistent with the need for an undamaged viral genome or
the presence of some replication intermediate to trigger the
pattern recognition receptor(s) that drive microglial produc-
tion of this chemokine. To clarify a role for IRF7 in dampen-
ing this response, primary cells isolated from IRF72/2 mice
were examined. In keeping with our in vivo findings,
CXCL13 protein levels were significantly increased in the
supernatants of stimulated microglia derived from IRF72/2
hosts (Fig. 3C). Thus, IRF72/2 microglia produced some
CXCL13 without any exogenous stimulation, showed height-
ened CXCL13 production compared with WT cells following
both NSV exposure or TLR9 ligation, and were now capable
of eliciting CXCL13 release in response to a TLR4 ligand
(Fig. 3C). Unlike our analysis of ex vivo microglia (Fig. 2B),
however, the absence of IRF7 and/or type-I IFN resulted in
higher cxcl13 transcript levels in cultured microglia both at
baseline and in response to NSV exposure (Fig. 3D). In con-
trast to CXCL13, IRF72/2 microglia did not overproduce
other pro-inflammatory cytokines or chemokines following
exposure to NSV or different TLR ligands (Fig. 3E–G, Supp.
Info. Fig. 2). As predicted, IRF72/2 cells did not make type-
I IFN in response to any of the different in vitro stimuli
examined (Fig. 3H,I).
Since IRF7 is a central regulator of type-I IFN produc-
tion by myeloid cells (Honda et al., 2005; Ning et al., 2011),
and because stimulated IRF72/2 microglia did not produce
measurable amounts of type-I IFN in response to a range of
stimuli (Fig. 3H,I), we hypothesized the existence of a nega-
tive feedback loop whereby type-I IFN specifically suppresses
microglial CXCL13 release. To investigate this possibility,
IRF72/2 microglia were stimulated in the presence of increas-
ing amounts of exogenous IFN-a. Treatment with this media-
tor caused CXCL13 protein levels to decline in a dose-
dependent manner following stimulation with NSV as well as
TLR4 or TLR9 ligation (Fig. 4A), while having no effect on
cell viability over the doses and culture intervals examined
(data not shown). Conversely, exogenous IFN-a had no
inhibitory effect on the production of other cytokines or che-
mokines by these innate immune cells (Fig. 4B,C). When the
effecte of exogenous IFN-a on stimulated CXCL13 produc-
tion by IRF72/2 microglia were examined at a transcriptional
level, treatment clearly suppressed the accumulation of cxcl13
transcripts (Fig. 4D).
Finally, to confirm the existence of this negative feed-
back mechanism, microglia prepared from IFNAR-deficient
mice were examined. These cells overproduced CXCL13 at
baseline, and they also made higher levels of CXCL13 com-
pared with WT cells in response to either NSV or a TLR9
ligand (Fig. 5). The addition of exogenous IFN-a had no
inhibitory effect on CXCL13 production in these cultures
FIGURE 4: Exogenous type-I IFN suppresses CXCL13 production by IRF72/2 microglia in a dose-dependent manner. A. Both NSV as well
as TLR9 and TLR4 ligands stimulated robust CXCL13 production by IRF72/2 microglia that was suppressed by the addition of increasing
concentrations of recombinant IFN-a to the cultures (*P<0.05 in treated vs. untreated cultures). B, C. The same treatment had no effect
on the stimulated production of the inflammatory cytokine, IL-12p40, and it had no effect or even the opposite effect on the stimulated
production of the non-lymphoid chemokine, CCL2 (*P<0.05 in treated vs. untreated cultures). D. Exogenous type-I IFN directly sup-
pressed the induction of cxcl13 transcript levels following either NSV or TLR9 stimulation.
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(data not shown). Taken together, these data show that local
production of type-I IFN by microglial cells specifically
inhibits release of the homeostatic chemokine, CXCL13, in
an autocrine and/or paracrine manner via IFNAR signaling
by acting to inhibit cxcl13 gene transcription or transcript
stability.
Discussion
The stromal cells found in B cell follicles of lymphoid organs
normally produce CXCL13 that signals through its cognate
receptor, CXCR5, to recruit B cells and Tfh cells to these
specialized structures (Allen et al., 2004; Ansel et al., 2000;
Campbell et al., 2003; Forster et al., 1996; Legler et al.,
1998; Moser et al., 2002; Muller et al., 2003). Outside of
maintaining homeostasis in lymphoid tissues, however, other
functions for CXCL13 remain incompletely defined. Data
generated in two infection models point to a role for
CXCL13 in recruiting B cells to non-lymphoid organs such
as the lung or liver where it helps organize local immune
responses against influenza or hepatitis B, respectively (Publi-
cover et al., 2013; Rangel-Moreno et al., 2007). Other evi-
dence suggests that ectopic expression of CXCL13 may
instead propagate destructive tissue inflammation; when trans-
genic mice are forced to express CXCL13 in pancreatic islets,
B cells accumulate abnormally, structures reminiscent of
lymphoid follicles appear, and animals develop diabetes
(Luther et al., 2000). Understanding whether and how
CXCL13 contributes to the pathogenesis of CNS diseases
remains obscure, in part because little has been published
describing either its source or the factors controlling its
expression in the brain. In experiments reported here, we find
that microglia are the main producers of CXCL13 in the
CNS of mice with virus-induced neuroinflammation, and
that type-I IFNs inhibit production of this chemokine by
these cells. We speculate that such a system may have evolved
to limit any destructive potential associated with chronic tis-
sue expression of this chemokine. It could also explain the
therapeutic benefit of exogenous type-I IFN (in this case,
IFN-b) in chronic CNS autoimmune diseases such as MS.
The recruitment and retention of antibody-secreting
cells (ASCs) to the meninges or the brain is an important
adaptive host response that occurs with many experimental
viral infections of the CNS. Here, locally generated antiviral
antibodies can neutralize extracellular virus particles or block
viral budding from infected cells to promote non-cytolytic
clearance of these pathogens (Phares et al., 2013). Where
they have been examined, B cell chemoattractant, survival
and differentiation factors are induced in the CNS during
these infections, although a specific role for CXCL13 in acute
viral clearance and recovery has not been confirmed in any of
these systems (Phares et al., 2013; Rainey-Barger et al.,
2011). Nonetheless, mice that recover from acute alphavirus
encephalitis because of early CNS viral clearance generate
virus-specific ASCs that reside long-term in the brain (Tyor
et al., 1992). These cells guard against late viral reactivation,
and it is likely that CXCL13 contributes to this chronic host
immune response (Rainey-Barger et al., 2011). Thus, the
ongoing actions of CXCL13 in the CNS may be adaptive for
the host in this recovery setting, and it may occur efficiently
since local type-I IFN levels have long since returned to base-
line following the acute infection.
Experimental evidence in animals also paradoxically
confirms an important role for CXCL13 in propagating aber-
rant CNS inflammation. Thus, ectopic lymphoid follicles
have also been described in the meninges of mice with EAE,
the principal animal model of MS (Magliozzi et al., 2004;
Peters et al., 2011). In this experimental system, however,
CXCL13 prolongs disease by sustaining myelin-specific
CD41 T cell responses rather than by recruiting CXCR51
B cells to the acutely inflamed CNS (Bagaeva et al., 2006;
Rainey-Barger et al., 2011). While CXCL132/2 mice are sus-
ceptible to EAE induction and develop early symptoms that
parallel WT animals, CNS inflammation subsides in
CXCL132/2 hosts who recover back to baseline instead of
showing persistent deficits that typifies WT disease (Bagaeva
et al., 2006). How CXCL13 actually sustains pathogenic
CD41 T cells in this setting remains unclear, but since it
brings lymphocytes into close physical proximity with DC in
lymphoid organs (Ansel et al., 2000; Forster et al., 1996;
Legler et al., 1998), it may serve a similar function in the
CNS. Regardless, if the main role of CXCL13 during EAE is
to sustain myelin-specific CD41 T cells once they have been
generated, then this chemokine becomes an excellent thera-
peutic target during more established stages of CNS
autoimmunity.
FIGURE 5: Genetic deletion of IFNAR enhances CXCL13 produc-
tion compared with WT microglia. Microglia cultured from
IFNAR-deficient mice made significantly higher amounts of
CXCL13 compared with WT cells under all culture conditions
examined (*P<0.05 in IFNAR2/2 vs. WT cultures).
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Only a small handful of studies have reported microglial
production of CXCL13. In a unique ex vivo slice culture
model using primate brain tissue, acute exposure to the Lyme
disease spirochete, Borrelia bergdorferi, induced CXCL13
staining of Iba-11microglia along with histochemical evi-
dence of apoptosis in both neurons and oligodendroglia
(Ramesh et al., 2008). Likewise, recent transcriptional profil-
ing of mouse microglia prepared and/or obtained from multi-
ple sources showed a gene expression pattern that was distinct
from other macrophage lineage cell types and included cxcl13
(Beutner et al., 2013). In our hands, NSV infection triggered
the generation of cxcl13 transcripts almost exclusively in
CD45dim/CD11b1 microglia when purified CNS mononu-
clear cells were studied directly ex vivo (Fig. 2A,B). Although
cxcl13 transcript levels present in WT and IRF72/2 microglia
(Fig. 2B) did not account for differences in CXCL13 protein
concentrations directly in CNS tissues (Fig. 1F,G), our in
vitro studies confirmed that the absence of IRF7 and/or type-
I IFN enhances cxcl13 transcript abundance in cultured
microglia (Fig. 2D) and that exogenous type-I IFN clearly
suppresses stimulated transcription of this gene in IRF72/2
cells (Fig. 4D). Ongoing studies aim to clarify the molecular
mechanisms underlying this transcriptional control.
Primary microglia clearly respond to extracellular IFN-b
(McManus et al., 2000), and emerging evidence suggests that
both type-I and type-II IFN can influence the expression of
CXCL13 outside the CNS. Thus, IFN-c is known to transi-
ently inhibit CXCL13 expression in lymph nodes in a way that
helps orchestrate local immune responses (Mueller et al.,
2007), while IFN-b can alter CXCL13 production by epithe-
lial cells in the thymus to influence germinal center formation
and autoantibody production in myasthenia gravis (Cufi et al.,
2014). Interestingly, type-I IFN signaling in DC actually stim-
ulates the generation of CXCR51 Tfh within lymph nodes
that, in turn, promote B cell immunity (Cucak et al., 2009).
Thus, while type-I IFN suppresses the generation of a signal
that recruits B cells into tissues and forms germinal centers, it
also promotes the development of a distinct T cell subset that
plays an important role to support these same processes. Our
data are the first to identify a similar regulatory process con-
trolling CXCL13 production in the CNS, even as it is clear
that B cells find CXCL13-independent pathways into the CNS
(Rainey-Barger et al., 2011), and that induction of this particu-
lar mediator has no direct impact on the outcome of the acute
infection being studied here (Figs. 1H,I).
Whether and how microglial production of CXCL13
might relate to the formation of ectopic lymphoid follicles
that specifically localize to the meninges during either infec-
tious or autoimmune CNS disorders remains unknown. NSV
infection, particularly in the IRF72/2 host, is simply too
rapid to allow these organized structures to form prior to
death. Our data do not exclude the possibility that a stromal-
like cell present in the meninges could also produce CXCL13
under the appropriate circumstances, and in doing so would
drive the focal accumulation and organization of lymphoid
cells at that site. On the other hand, there are also examples of
where meningeal cells clearly influence brain parenchymal
structure and function (Derecki et al., 2010), so it is not incon-
ceivable that local CXCL13 production by parenchymal micro-
glia could influence events in the overlying meninges. Finally,
construction of a transgenic mouse where inducible expression
of CXCL13 will lie under control of the transthyretin pro-
moter, thus causing selective chemokine expression in the
meninges and choroid plexus (Schreiber, 2002), is underway
and could be another way to illuminate the roles of parenchy-
mal- versus meningeal-derived CXCL13. One hypothesis to be
explored in such mice is that the induction of EAE could
potentially result in the formation of meningeal lymphoid fol-
licles, thereby allowing investigation of their role in more
chronic progressive forms of CNS demyelinating disease.
In conclusion, we demonstrate the microglia are an
important source of CXCL13 production in the acutely
inflamed brain, and in vitro experiments confirm that type-I
IFN selectively inhibits microglial production of CXCL13 in
a dose-dependent manner. Our results confirm the existence
of a novel regulatory pathway controlling expression of this
lymphoid chemokine within the CNS. Further elucidation of
these events could have important implications for under-
standing chronic B cell immunity within the CNS and they
could even shed light on how exogenous IFN-b functions in
the clinical management of patients with MS.
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